See the DrugPatentWatch profile for Vyondys
Who qualifies for Vyondys 53 (golodirsen) and what “eligibility” usually means
Vyondys 53 is used for people with Duchenne muscular dystrophy (DMD) who have a specific genetic change: a confirmed mutation amenable to skipping exon 53 [1]. Eligibility, in practice, depends on both diagnosis and genetic testing results that show the treatment can target the relevant exon.
What diagnosis details are required for Vyondys to be considered
To be eligible, patients generally need:
- A diagnosis of Duchenne muscular dystrophy (DMD) [1]
- Confirmation that their mutation is amenable to exon 53 skipping (typically established by genetic testing) [1]
Is age part of Vyondys eligibility?
The available label information indicates the drug is used in certain pediatric patients with DMD and exon 53–amenable mutations [1]. Exact age cutoffs are typically handled by the prescribing label and local prescribing rules.
Can someone be eligible without exon 53–amenable mutation?
If a person does not have a mutation amenable to exon 53 skipping, Vyondys is not the indicated treatment for DMD exon skipping. In that case, other approaches (including other exon-skipping therapies, if mutation-appropriate) may be considered, depending on the specific genetic finding.
What genetic tests are used to determine eligibility for exon 53 skipping?
Eligibility is based on whether the patient’s mutation is amenable to skipping exon 53, which is established through genetic testing that identifies the DMD mutation and its “skipping” suitability [1].
How clinicians confirm eligibility before prescribing
Clinicians typically verify eligibility by:
- Confirming DMD diagnosis
- Ordering or reviewing genetic testing results that show exon 53 amenability
- Matching the patient’s mutation to exon-skipping criteria stated for Vyondys 53 [1]
Practical next step if you’re checking eligibility
Ask the neuromuscular specialist (or treatment center) whether the patient’s DMD genetic report explicitly indicates exon 53 skipping is applicable, and request documentation showing “mutation amenable to exon 53 skipping,” which is the key eligibility criterion tied to the Vyondys indication [1].
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207646